Aldeyra Therapeutics, Inc. will run an additional dry eye chamber trial of reproxalap with a primary endpoint of ocular discomfort, using a parallel group design, that will allow it to refile for approval later this year, per an agreement with the US Food and Drug Administration.
Key Takeaways
-
Aldeyra will initiate a Phase III dry eye chamber trial during the first half of 2024 to demonstrate reproxalap’s efficacy against ocular discomfort, a symptom of dry eye disease.
The FDA issued a complete response letter (CRL) for reproxalap last November, requesting further demonstration of efficacy on a symptom...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
